VentriPoint Diagnostics Ltd.VPT - TSX Venture
Shares issued: ~79.4 million
Fully diluted: ~99.6 million
************************
Linked here ..... is today’s’ news release appointing Dr. Robyn Barst to Ventripoint’s Scientific Advisory Board.
This announcement is a coup as Dr. Barst is a noted, leading cardiologist in Pulmonary Hypertension, which is abnormally high blood pressure in the arteries of the lungs, making the right side of the heart work extremely hard. Her vast experience will prove valuable with VPT planning the imminent launch of its PHT trials. Dr. Barst will be the principal investigator for the trials in the United States.
PHT is seen as having the potential to be an annual $1 billion market for Ventripoint’s 3D technology. Dr. Barst’s involvement is expected to drive early support for the research component.
For some time Ventripoint has been building the PH database. VPT began internally testing the database at the end of March and is now preparing to deploy VMS units into leading centres for validation trials. The objective is to prove that VMS is equal to MRI images but is much faster, convenient and affordable. The key to Ventripoint’s technology is its ability to create 3D images of the heart from ultrasound images.
Dr. Barst as the principal investigator will pick the prime sites for the trials . Dr. Barst continues to be on a number of FDA advisory committees. Her expertise will be invaluable in this inititiative.
Understandably, CEO Dr. George Adams is very pleased to have someone of Dr.Barst’s calibre join the team, as it is another step in proving VPT as an innovator of providing imaging systems to a global market. Dr. Barst is equally motivated as she believes that the VMS system has strong potential.
As we have mentioned before, each step forward brings the company closer to full scale commercialization.
Dr. Barst bio:
Robyn J. Barst, MD, FAHA, FACC, FCCP, FAAP
Professor Emeritus of Pediatrics (in Medicine)
Columbia University College of Physicians & Surgeons
New York, NY USA
Director of the New York Pulmonary Hypertension Center at Columbia University (1982-2008)
Dr. Barst received her undergraduate degree from the University of Rochester, Rochester, NY and her medical degree (Alpha Omega Alpha and the Distinguished Medical Alumnus Award of the School of Medicine) from the University of North Carolina, Chapel Hill, NC. She completed a residency in pediatrics, and two fellowships in pediatric cardiology and pulmonary medicine at Columbia University College of Physicians & Surgeons in New York, NY. Following her training, Dr. Barst was recipient of the AHA Clinician-Scientist Award and the NHLBI Clinical Investigator Award.
Dr. Barst founded the first pediatric and adult pulmonary hypertension center in 1982 and served as its director until 2008. She serves as a scientific advisor to pharmaceutical companies worldwide developing novel drugs for pulmonary hypertension. She is a consultant to the FDA, the EMEA and the NHLBI. She also served as Chair of the AHA’s Council on Cardiovascular Disease in the Young.
0 comments:
Post a Comment